Discover.
Launch.
Build.
Transform.
● Recent Highlights
Seaport Therapeutics
Seaport Therapeutics is a clinical-stage biopharmaceutical company that is charting a proven path in neuropsychiatry.
Seaport Therapeutics
Clasp Therapeutics
Clasp Therapeutics, a biotechnology company bringing unparalleled precision to immuno-oncology using next-generation T cell engagers (TCEs).
Clasp Therapeutics
Synnovation Therapeutics
Synnovation Therapeutics is a precision medicine company developing small molecule therapies optimized to achieve best-in-class pharmacology against highly validated disease targets.
Synnovation Therapeutics
bluebird bio
The FDA announced the approval of bluebird’s Lyfgenia for the treatment of sickle cell disease. Lyfgenia represents one of the first cell-based gene therapies for the treatment of sickle cell disease (SCD) in patients 12 years and older. SCD is a rare, debilitating and life-threatening blood disorder with significant unmet need. Gene therapy holds the promise of delivering more targeted and effective treatments, especially for individuals with rare diseases where the current treatment options are limited.
Living our core values.
One of Third Rock’s founding core values is to do the right thing. We believe diversity fuels innovation and are committed to fostering inclusion and diversity in all we do. That's why we are proud to be one of the founding members of the Bioscience & Investor Inclusion Group (BIIG), a coalition created to address diversity, equity and inclusion in the life sciences sector.
Learn more